



PRESS RELEASE

For Immediate Release

Latest Clinical Data on the Corgenix AspirinWorks[®] Test Kit to be Presented at the International Society on Thrombosis and Hemostasis (ISTH) Meeting from July 6-12, 2007

NEW ASPIRINWORKS[®] TEST FOR ASPIRIN EFFECTIVENESS NOW AVAILABLE TO CLINICAL TESTING LABORATORIES

DENVER, Colo. — June 21, 2007 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced that the latest clinical data on its newest diagnostic product, the AspirinWorks[®] Test Kit, will be released at the XXIst Congress of the International Society on Thrombosis and Hemostasis (ISTH) and the 53rd Annual Scientific and Standardization Committee (SSC) Meeting to be held in Geneva, Switzerland from July 6-12, 2007. This meeting is recognized as one of the most important international events relating to thrombosis and abnormalities of hemostasis and vascular biology.

At this congress, hematology experts looking at aspirin resistance will present several important papers that compare AspirinWorks[®] to existing research technologies used for measuring 11-dehydro thromboxane B₂. Douglass Simpson, Corgenix President and Chief Executive Officer said, "We are pleased to see this new data presented at the ISTH and SSC meetings. We believe this test targets a significant worldwide market. As new clinical findings continue to validate the utility of AspirinWorks[®], we anticipate it will become the standard of care worldwide."

Following the recent FDA clearance of the AspirinWorks[®] Test Kit, many principle clinical laboratories in the U.S. are now evaluating and validating the new product. The new kit, already CE marked and available in Europe, will be sold through Corgenix' U.S. sales force and marketed internationally through its established network of distributors.

"Research has shown that up to 25 percent of individuals may be non-responsive to aspirin's benefits, increasing their risk of death from heart disease more than three-fold," said Corgenix Clinical Affairs Director Gordon Ens. "This test can determine if aspirin fails to elicit an effect, thereby allowing physicians to individualize their patient's therapy."

Unlike invasive platelet function tests requiring freshly drawn blood that must be evaluated within at least four hours, AspirinWorks[®] is performed on a random urine sample easily obtained in a doctor's office.

Ens stated that with the FDA clearance, all doctors in the U.S. are able to order AspirinWorks[®] and he expects the test will be routinely offered in many clinical laboratories by the end of 2007.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail techsupport@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Investor Contact:

The Investor Relations Group
Dian Griesel/ Erika Moran
Phone: 212-825-3210
Fax: 212-825-3229

Media Contact:

Dan Snyders
Vice President, Public Relations Supervisor
Armada Medical Marketing
Phone: 303-623-1190 x 230
Fax: 303-623-1191
dan@armadamedical.com